Latest News
Sankyo Co., Ltd.
- Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
- AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
- AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab
- AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
- Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
- Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy
- AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics
- A New Chapter for Luis Chia After 7 Years at Daiichi Sankyo
- Daiichi Sankyo, MSD withdraw cancer drug application
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
- Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
- Daiichi Sankyo, Merck Pull Ifinatamab Deruxtecan BLA in SCLC
Headlines from the last 30 days, linking to the original publishers. See all market news →